sgx523
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00607399)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1- Mol. weight
- 359.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1236107 ↗
Also known as
- 6-(6-(1-methyl-1h-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
- sgx523
- sgx523
- sgx523
- sgx 523
- sgx-523
- sgx-523
- sgx-523
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00606879 | Phase 1 | Jan 1, 2008 | Premiere Oncology, SCRI Development Innovations, SGX Pharmaceuticals |
| NCT00607399 | Phase 1 | Jan 1, 2008 | Premiere Oncology, Scottsdale Healthcare, SGX Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Premiere Oncology | For profit | 2 | 0 | 1 | 2008 |
| SGX Pharmaceuticals | For profit | 2 | 2 | 1 | 2008 |
| Scottsdale Healthcare | Academic/Hospital | 1 | 0 | 1 | 2008 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1